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Abstract. In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all
pregnant women receive sulfadoxine–pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled ante-
natal care visit after 16 weeks of gestation. Human immunodeficiency virus (HIV)–positive women should receive
co-trimoxazole prophylaxis for HIV and not SP, but many still receive SP. We sought to determine whether increased
dosage of SP is still associated with a reduced risk of low birth weight (LBW) in an area where malaria transmission
is low. Our secondary objective was to determine whether any association between SP and LBW is modified by
receipt of antiretroviral therapy (ART). We analyzed data routinely collected from a cohort of HIV-positive pregnant
women with singleton births in Lusaka, Zambia, between February 2006 and December 2012. We used a log-
Poisson model to estimate the risk of LBW by dosage of SP and to determine whether the association between SP
and LBW varied by receipt of ART. Risk of LBW declined as the number of doses increased and appeared lowest
among women who received three doses (adjusted risk ratio [ARR] = 0.78; 95% confidence interval [CI] = 0.64–0.95).
In addition, women receiving combination ART had a higher risk of delivering an LBW infant compared with women
receiving no treatment or prophylaxis (ARR = 1.18; 95% CI = 1.09–1.28), but this risk was attenuated among women
who were receiving SP (risk ratio = 1.09; 95% CI = 0.99–1.21). SP was associated with a reduced risk of LBW in HIV-
positive women, including those receiving ART, in a low malaria prevalence region.
INTRODUCTION
In Zambia, the prevalence of human immunodeficiency
virus (HIV) among pregnant women is 22%,1 and malaria
infection accounts for approximately 30% of outpatient
visits nationally, but varies considerably by region.2,3 HIV-
infected pregnant women have reduced antimalarial immu-
nity4 and, when infected, higher burdens of the malaria
parasite.5–9 Malaria-infected pregnant women have increased
CD4+ cell activation, upregulation of proinflammatory cyto-
kines, and increased HIV RNA viral loads.5,10 Considerable
efforts have been made to combat malaria burden in Zambia,
and while there has been a resurgence of malaria in the
country, in Lusaka Province, malaria transmission is very low
with < 1% parasite prevalence.2
Distinct guidelines for the treatment and prophylaxis of
HIV and malaria infection, particularly for pregnant women,
may not be appropriate for the overlap in these epidemics.
For example, Zambian guidelines recommend malaria pro-
phylaxis with sulfadoxine–pyrimethamine (SP) for all preg-
nant women during the course of pregnancy given monthly
at each scheduled antenatal care (ANC) visit starting at
16 weeks of gestation to achieve a total of three of more
doses.3,11,12 HIV-positive women are recommended to
receive co-trimoxazole (CTX) prophylaxis and not SP, but
many still receive SP with or without CTX.13 SP is a folic
acid antagonist that disrupts replication of the malaria para-
site and is not recommended for HIV-infected pregnant
women on CTX prophylaxis, owing to the redundant mecha-
nism of action leading to increased toxicity.11,14 In 2013,
Zambia adopted the “Option B+ strategy,” which recom-
mends that all HIV-infected pregnant women start antiretro-
viral therapy (ART) during pregnancy and continue it for life,
regardless of their CD4 count.13 These recommendations
have resulted in a large number of HIV-positive women in
sub-Saharan Africa, and specifically in Zambia, who are
receiving both ART and SP during pregnancy. Although
guidelines recommend that HIV-positive women who are
pregnant receive CTX without SP, real-world application
of HIV and malaria guidelines in pregnancy suggests that
HIV-positive women are receiving both ART and SP, with
or without CTX.15
SP has been associated with a decreased risk of low
birth weight (LBW) among pregnant women in general16–18
and among HIV-infected pregnant women in specific.19 A
Cochrane review of trials comparing dosing regimens found
that infants born to HIV-positive pregnant women receiving
three or more doses of SP weighed more than those born to
mothers receiving two doses.19 However, one trial in Ndola,
Zambia, found no difference between those receiving the
standard two doses of SP compared with three or more
doses.20 All prior studies have been in malaria-endemic
areas and none have considered how simultaneous receipt
of both ART and SP in HIV-positive pregnant women may
influence risk of LBW.
In our study population in Lusaka, Zambia, a low malaria
burden area, current national antenatal guidelines continue to
recommend that HIV-infected pregnant women, except those
receiving CTX prophylaxis, receive three or more doses of SP
in pregnancy. The primary objective of this study was to
determine whether increased dosage of SP is still associated
with a reduced risk of LBW in an area where malaria trans-
mission is low. The secondary objective was to determine
whether any association between SP and LBW is modified by
administration of antiretroviral therapy (ART).
*Address correspondence to Marie C. D. Stoner, Department of
Epidemiology, University of North Carolina at Chapel Hill, 135 Dauer
Drive, 2101 McGavran-Greenberg Hall, Chapel Hill, NC 27599-7435.
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MATERIALS AND METHODS
Lusaka, Zambia, is city of 2 million people with 25 public
health sector facilities, including the University Teaching
Hospital, which provide ANC and delivery services to preg-
nant women. We conducted analysis of data collected pro-
spectively through the Zambia Electronic Perinatal Record
System (ZEPRS). ZEPRS is a patient-linked electronic health
record system that serves all pregnant women receiving
pregnancy care in the Lusaka Urban District.1 Data are col-
lected from patients on demographic characteristics, medical
history, and ANC, and delivery information for both the mother
and infant.1
Our primary analysis included singleton births to HIV-
positive women with an initial ANC visit between February 1,
2006 and December 31, 2012. Women who were HIV sero-
negative or whose status was unknown, who delivered out-
side of the ZEPRS catchment area, who delivered multiple
gestation, and who had missing information on infant birth
weight or gestational age were excluded. The outcome of
LBW was defined as an infant weighing < 2,500 g.21 The
number of doses of SP received was recorded at each ANC
visit at a ZEPRS clinic. Our exposure was defined categori-
cally as the maximum number of doses of SP received dur-
ing any ANC visit over the course of the pregnancy. Women
at the ZEPRS facilities can receive up to three doses of SP.
Gestational age was assessed by last menstrual period.
Hypertension was defined as any diagnosis of hypertension
during ANC or delivery, and hemoglobin was measured at
first ANC visit. Although CTX prophylaxis is recommended
for all HIV-positive women and SP is not recommended for
women receiving CTX, we were unable to determine which
women in our cohort were receiving CTX prophylaxis; ART
was defined as initiation of a combination antiretroviral regi-
men with a goal of viral suppression, as described in World
Health Organization (WHO) guidelines.13
We compared maternal and newborn characteristics of
HIV-positive pregnant women by number of SP doses received
during ANC. Frequencies and percentages were reported for
categorical measures. Medians with the interquartile range were
reported for continuous measures. We used the Cochran–
Mantel–Haenszel nonzero correlation coefficient, row mean
score statistic or Kruskal–Wallis test to test differences
between number of SP doses received and ordinal, nominal,
or continuous variables, respectively. We fit a log-Poisson
regression model to estimate the risk of LBW by dose of SP.22
FIGURE 1. Flow diagram of inclusion criteria for a Zambian cohort of pregnant women from the Zambia Perinatal Electronic Record System
in Lusaka, Zambia (February 2006–December 2012).
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The log-Poisson model approximates a log binomial.22 Gen-
eralized estimating equations with an unstructured correlation
structure estimated robust 95% confidence intervals (CIs) that
accounted for repeat deliveries over the study period. Covari-
ates were included in multivariable analysis that were
deemed clinically meaningful and that were significant in
univariable analysis. Our final model was adjusted for age,
parity, hypertension, body mass index (BMI), hemoglobin,
prior LBW infant, receipt of ART, CD4+ lymphocyte count, and
number of ANC visits. Correlation between parity and prior
LBW was examined but was not high (0.184). Clinical diagno-
sis of malaria (3.2%) (without laboratory confirmation) was
not significantly associated with LBW (risk ratio [RR] = 1.04;
95% CI = 1.90–1.21), did not substantially change the coeffi-
cients for dose of SP (< 10%), and a likelihood ratio test com-
paring models with and without the variable was not significant
(χ2 = 0.33, P = 0.564, df = 1). Therefore, malaria diagnosis
was not included in the final model due to the large
number of missing data (24%). We added an interaction
term between SP and ART to the adjusted model to esti-
mate the association between ART and LBW infant strati-
fied by receipt of any SP (yes/no). We compared the fit of
the adjusted model with and without an interaction term
using a log-likelihood ratio test for multiplicative interac-
tion. We also calculated the attributable proportion of LBW
infants prevented by the additive interaction between SP
and ART, adjusting for all other covariates.23 Because women
who present for a first antenatal visit later in pregnancy may
have fewer opportunities to receive three doses of SP, we
performed a subanalysis by restricting the cohort to those
HIV-infected women whose first ANC occurred at or before
22 weeks gestation. In a final analysis, we compared our
results to a model restricted to HIV-uninfected women from
the original cohort. SP has been shown to have an effect in
both HIV-uninfected and infected women, and we hoped to
determine whether our results from a low prevalence area
were similar between these populations. Subanalyses were
adjusted for all covariates included in the final adjusted
model. All analyses were conducted with SAS version 9.3
(SAS Institute, Cary, NC).
RESULTS
A total of 48,246 mother–infant pairs met eligibility criteria
and were included in the analysis cohort. Most women were
excluded because they were HIV uninfected/unknown
(N = 179,948) or did not have delivery information available
(N = 107,154; Figure 1). Among HIV-positive women included
in our study cohort, the majority received one dose of SP
(N = 22,908; 47.5%) or no doses (N = 12,052; 25.0%). The
remainder received either two (N = 8,349; 17.3%) or three
doses of SP (N = 4,937; 10.0%).
Women receiving more doses of SP were less likely to
have a teen pregnancy, and more likely to have higher parity,
higher BMI, higher hemoglobin concentration, more ANC
visits, and to have had a prior LBW or a diagnosis of hyper-
tension during ANC or pregnancy (Table 1). Number of doses
of SP did not correspond directly with number of ANC visits
with some women reporting more doses than ANC visits.
Among women who did not receive (N = 8,671; 71.9%)
or received only one dose (N = 16,228; 70.8%), most women
had only one ANC visit. Approximately 40% of women (N =
1,991) who received three doses of SP had more than three
ANC visits. CD4+ T-lymphocyte counts did not vary by dose
of SP.
The percentage of women who delivered an LBW infant
decreased with each additional dose of SP. The lowest per-
centage of LBW was among women who received three
(N = 401; 8.1%), followed by two (N = 920; 11.0%) doses
of SP (Figure 2; Table 2). Gestational age at birth was
slightly higher among women who received three doses
FIGURE 2. Percentage and 95% confidence intervals for low birth weight infants (< 2,500 g) by dose of sulfadoxine–pyrimethamine.
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(39 weeks), and these women were the least likely to have
a stillbirth (N = 86; 1.7%).
In unadjusted analysis, LBW was associated with age, par-
ity, hypertension, CD4 count, hemoglobin concentration,
number of ANC visits, type of ART, prior LBW, and number
of doses of SP (Table 2). The risk of LBW in women receiving
three doses was half of that faced by women receiving no
doses (RR = 0.54; 95% CI = 0.49–0.60). In multivariable anal-
ysis, risk of LBW declined with number of doses received
(one dose: adjusted risk ratio [ARR] = 0.98; 95% CI = 0.91–
1.06, two doses: ARR = 0.87; 95% CI = 0.76–1.00, three
doses: ARR = 0.78; 95% CI = 0.64–0.95). When restricted to
women with an initial ANC visit at or before 22 weeks gesta-
tional age, results were similar. Risk of LBW declined with
increased number of doses (one dose: ARR = 1.00; 95% CI =
0.90–1.12, two doses: ARR = 0.97; 95% CI = 0.82–1.14,
three doses: ARR = 0.78; 95% CI = 0.62–0.99). Among HIV-
uninfected women, the risk of LBW again declined with
increased number of doses of SP (one dose: ARR = 0.99;
95% CI = 0.92–1.06, two doses: ARR = 0.95; 95% CI =
0.85–1.11, three doses: ARR = 0.81; 95% CI = 0.70–0.93).
In multivariable analysis, the risk of LBW among women
receiving combination ART was 1.18 (95% CI = 1.09–1.28)
times the risk in women not receiving ART (Table 3). When
stratified by SP use, receipt of ART was not associated with
LBW among women receiving SP (ARR = 1.09; 95% CI =
0.99–1.21) (Figure 3). Among women not receiving SP, women
receiving suppressiveARThad1.31 (95%CI=1.17–1.47) times
the risk of LBW compared with women not receiving com-
bination ART. A likelihood ratio test comparing adjusted
models with and without an interaction term between SP
and ART indicated a multiplicative interaction at an alpha
level of 0.05 (χ2 = 4.61, df = 1, P = 0.03). The attributable
proportion of LBW due to the additive interaction between
SP and ART was −0.20 indicating that there are 20%
fewer LBW infants due to the additive interaction between
SP and ART. In other words, because some women were
receiving both drugs, there were 20% fewer LBW infants
in our population than would have been expected.
DISCUSSION
In this population with a low malaria burden, we observed
an inverse dose–response relationship between the number
of doses of SP received and risk of LBW. Risk of LBW
TABLE 2
Unadjusted and adjusted* RR and 95% CIs for the relationship between dose of SP and LBW in Lusaka, Zambia
Characteristic Unadjusted RR (95% CI) Adjusted RR (95% CI)
Adjusted RR (95% CI)
HIV uninfected (N = 179,948)
Adjusted RR (95% CI)
EGA ≤ 22 weeks (N = 24,376)
Maternal Age
< 20 1.34 (1.24–1.44) 1.29 (1.15–1.44) 1.41 (1.32–1.51) 1.16 (1.00–1.35)
20–34 1 1 1 1
> 35 1.06 (0.98–1.13) 0.94 (0.84–1.06) 1.07 (0.95–1.20) 0.94 (0.79–1.12)
Parity, median
0 1 1 1 1
≥ 1 0.81 (0.77–0.85) 0.77 (0.71–0.83) 0.63 (0.59–0.67) 0.82 (0.74–0.91)
Hypertension in ANC or delivery
No 1 1 1 1
Yes 1.30 (1.19–1.41) 1.55 (1.38–1.74) 1.67 (1.52–1.82) 1.47 (1.26–1.72)
BMI
< 18.5 1.86 (1.67–2.09) 1.89 (1.65–2.17) 1.41 (1.23–1.60) 1.85 (1.56–2.19)
18.5–30 1 1 1 1
> 30 0.56 (0.48–0.64) 0.58 (0.49–0.70) 0.68 (0.61–0.77) 0.64 (0.49–0.82)
Dose of SP
None 1 1 1 1
One dose 1.01 (0.96–1.06) 0.98 (0.91–1.06) 0.99 (0.92–1.06) 1.00 (0.90–1.12)
Two doses 0.74 (0.69–0.80) 0.87 (0.76–1.00) 0.95 (0.85–1.06) 0.97 (0.82–1.14)
Three doses 0.54 (0.49–0.60) 0.78 (0.64–0.95) 0.81 (0.70–0.93) 0.78 (0.62–0.99)
CD4 count at first ANC visit
< 200 1.53 (1.42–1.66) 1.40 (1.26–1.56) – 1.46 (1.26–1.69)
200–350 1.18 (1.10–1.27) 1.11 (1.01–1.22) – 1.16 (1.01–1.32)
350–500 1.10 (1.02–1.18) 1.06 (0.96–1.17) – 1.16 (1.02–1.33)
≥ 500 1 1 – 1
HGB
< 8 1.73 (1.52–1.98) 1.47 (1.22–1.78) 1.60 (1.22–2.09) 1.43 (1.09–1.87)
8–10 1.17 (1.09–1.25) 1.15 (1.05–1.26) 1.25 (1.11–1.41) 1.23 (1.09–1.39)
> 10 1 1 1 1
No. of ANC visits
1 2.03 (1.82–2.26) 2.09 (1.69–2.58) 2.42 (2.02–2.90) 2.23 (1.75–2.85)
2 1.61 (1.44–1.81) 1.63 (1.31–2.01) 1.98 (1.66–2.36) 1.83 (1.44–2.33)
3 1.20 (1.05–1.36) 1.29 (1.04–1.60) 1.49 (1.26–1.77) 1.46 (1.14–1.85)
> 3 1 1 1 1
Type of ART
No treatment or AZT/NVP prophylaxis 1 1 – 1
Combination ART 1.22 (1.17–1.28) 1.18 (1.09–1.28) – 1.16 (1.04–1.28)
Prior LBW
No 1 1 1 1
Yes 1.31 (1.22–1.41) 1.41 (1.27–1.58) 1.92 (1.74–2.12) 1.43 (1.24–1.66)
ANC = antenatal care; ART = antiretroviral therapy; BMI = body mass index; CI = confidence interval; EGA = estimated gestational age; HGB = hemoglobin; HIV = human immuno-
deficiency virus; LBW = low birth weight; RR = risk ratio; SP = sulfadoxine–pyrimethamine.
*Adjusted for age, parity, hypertension, BMI, hemoglobin, prior LBW infant, receipt of ART, CD4+ lymphocyte count, and number of ANC visits.
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declined as number of doses increased and was lowest
among women who received the recommended three doses.
This pattern remained after restricting the sample to women
who presented to care earlier and who were HIV uninfected.
The majority of women (52%) received both ART and at least
one dose of SP during ANC and 10.2% of women (N =
4,937) received the three doses of SP during pregnancy. In
addition, women receiving combination ART had a higher
risk of delivering an LBW infant, but this risk was attenu-
ated among women who were simultaneously receiving
SP. SP reduces risk of LBW in HIV-positive women, includ-
ing those receiving ART. Because the malaria prevalence in
Lusaka is very low, we hypothesize that it is unlikely that
these apparent benefits can be solely ascribed to SP’s anti-
plasmodial effect.
SP is used for prophylaxis because it eliminates parasites
that persist asymptomatically as they emerge from the
liver.25 However, there is no consensus about the specific
mechanism by which SP increases birth weight.24 We
observed an association between SP and LBW in a setting
where few women are overtly infected with malaria. Our
results suggest that SP may be treating or preventing
another infection or interacting with the maternal immuno-
logical system thereby decreasing risk of LBW. Because
CTX information was not available, it is also possible that
CTX, which has a similar mechanism of action, is working
through these pathways. Infections of both the upper and
the lower genital tracts have been linked to increased risk
of preterm birth and LBW. Antimicrobial treatment to treat
infections has been shown to reduce risk of preterm birth.25
It is possible that SP reduces LBW by reducing risk of
infection and preterm birth. Further studies are needed to
confirm these results and understand the mechanism for
this relationship.
SP is contraindicated for women receiving CTX prophy-
laxis for HIV due to the redundant mechanism of action and
potential for adverse toxicity events. WHO guidelines for the
treatment of HIV recommend that all HIV-positive women
receive CTX during pregnancy.11 We were unable to deter-
mine whether women in our cohort were receiving both CTX
and SP, but given the large number of women on SP in our
study, it is possible that implementation of the recommenda-
tions is not optimal and some were receiving both drugs.
Despite this limitation, a study in a comparable population in
Malawi found that even among women who do receive both
SP and CTX, there might be a beneficial reduction in anemia
and malaria parasitemia.15 Another study found that while
SP should not be coadministered with CTX due to increased
toxicity, women receiving CTX may still benefit from addi-
tional antimalarial prophylaxis.26 Women receiving CTX
should not be given SP; therefore, more research is
needed to determine how CTX may factor into our findings
and how other antimalarial drugs compare, particularly as
CTX has also been associated with malaria and LBW.
A growing body of evidence supports the hypothesis that
ART increases the risk of preterm birth in sub-Saharan
Africa, perhaps through inflammation and/or immune acti-
vation.27–33 ART may potentiate this risk through a similar
mechanism.27,28 Limited research exists regarding the inter-
action between antiretroviral and antimalarial drugs, but the
protease inhibitor component of ART may have antimalarial
properties by inhibiting parasite growth.14,34,35 The anti-
malarial drugs chloroquine and hydroxychloroquine have
also been shown to have antiretroviral activity in vitro and
in vivo.14 In our study cohort, a large percentage (N = 7,367;
53%) of women who were receiving ART were also receiving
SP. Our results show an attenuated risk of LBW associated
with ART in women who are simultaneously receiving SP.
The mechanism for this relationship is unclear, but may be
related to a reduced inflammatory response during preg-
nancy.14 Although HIV-positive women should receive CTX
and not SP, there are now a large number of HIV-pregnant
women in sub-Saharan African who are receiving both SP
and ART. Our study is the first study to examine whether
receipt of SP for malaria prophylaxis modifies the risk of
LBW associated with ART use. More studies are needed to
confirm this association.
We acknowledge several limitations to our analysis. First,
we are using clinical data collected at primary and tertiary
care facilities in Zambia where missing data are common.
Many of the women who were excluded were missing data
on delivery because they did not return to a ZEPRS facility
to deliver. Women who return to a facility may be more
likely to have high-risk pregnancies or be different in other
ways from women who deliver at home. However, a prior
publication found that women with delivery information
in ZEPRS did not differ in any clinically significant way
from women without delivery information.36 Second, we do
not have complete information available about laboratory
malaria diagnosis, CTX prophylaxis, socioeconomic status,
or HIV RNA viral load and were unable to adequately exam-
ine or control for these factors. Third, there are women in
our study with more doses of SP than ANC visits. This
mismatch suggests that women had missed visits that were
not recorded in the system or had other visits outside
of ZEPRS facilities. Fourth, some women who present to
FIGURE 3. Adjusted risk ratios and 95% confidence intervals (CIs)
for the relationship between antiretroviral therapy (ART) use and low
birth weight–stratified receipt of sulfadoxine–pyrimethamine (SP). *
*All adjusted for age, parity, hypertension during antenatal care
(ANC) or delivery, body mass index, receiving ART, receiving SP,
hemoglobin, baseline syphilis, CD4+ lymphocyte count, prior low
birth weight, and number of ANC visits. Modeled using a log-Poisson
model with robust standard errors to estimate the RR. **Likelihood
ratio test comparing adjusted models with and without an interaction
term between SP and ART: χ2 = 4.61, df = 1, P = 0.0318. ***Overall
RR = 1.18 (95% CI = 1.09–1.28), not receiving SP = 1.31 (95% CI =
1.17, 1.47), receiving SP = 1.09 (95% CI = 0.99, 1.21). ****Interaction
contrast ratio = (1.11 − [1.02 + 1.31 − 1]) = −0.22 (95% CI = −0.60,
0.16); additive attributable proportion = 0.22/1.11 = −0.20.
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ZEPRS clinics travel from peri-urban areas around Lusaka
where transmission of malaria is much higher.37 Fifth, while
we did control for CD4+ count in the model for the rela-
tionship between ART and LBW, there may still be some
confounding by indication. Finally, ultrasound dating is not
widely used in our setting and thus information about gesta-
tional age, including estimated gestational age at first ANC
visit, is not particularly reliable.38
Alongside its primary benefit in malaria control, SP may
have an additional secondary benefit of reducing risk of LBW
in HIV-infected women, including those receiving ART.
Among HIV-positive women, increased dosage of SP was
associated with a decreased risk of LBW. The most robust
association was seen among women who received the
recommended three doses; however, many women present to
ANC in advanced gestation and may not have sufficient
time to receive three doses. Efforts are needed to
encourage women to attend and present earlier to ANC.
Further studies are also needed to better understand the
mechanism for the relationship between SP and LBW in a
low malaria prevalence setting, and determine how CTX
prophylaxis for HIV versus SP affect risk of LBW in areas
where SP is recommended.
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